Abstract
BackgroundAlthough efficacy of biologics approved for moderate to severe RA is similar in clinical trials, there may be differences in individual patients. As choices for biologic treatment increase, switching, discontinuation,...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have